REG - ValiRx PLC - Director Appointment

ValiRxAnnouncement

11/10/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221011:nRSK3880Ca&default-theme=true

RNS Number : 3880C  ValiRx PLC  11 October 2022

 

ValiRx plc

 

("ValiRx" or the "Company")

 

Director Appointment

 

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health is pleased to announce
that, further to the announcement of 6 September 2022, the Company has
appointed Ms Stella Panu as Non-executive Director with immediate effect,
following completion of standard regulatory due diligence.

 

Stella was a founding Partner of Maven Capital Partner UK LLP ("Maven"), an
investment management company, created after a management buyout of the
private equity business of Aberdeen Asset Management plc ("AAM") in 2009, and
led the business through to its sale in July 2021.  Maven has a focus on
venture growth and innovation and during her time at Maven, Stella led the AIM
Investment team and was the lead investor in private equity across Maven.
Stella was recently appointed a Non-executive Director of Vianet Group plc, an
international provider of actionable data and business insight through devices
connected to its Internet of Things platform ("IOT"). Having previously been
at AAM and Seymour Pierce Ltd and had seats on numerous company boards, Stella
brings with her a wealth of private equity M&A and AIM experience.

Stella has also previously worked for Pricewaterhouse Coopers, The World Bank,
and Raifessen Investment Fund and holds a Bachelor's degree in Economics and
an MA in Applied Economics and Statistics.

 

Further disclosures on Ms Stella Panu as required under Schedule Two,
paragraph (g) of the AIM Rules for Companies are included in the Appendix
below.

 

Dr Suzy Dilly, CEO commented: "We are delighted to formally welcome Stella to
the Board.  I look forward to working closely with Stella, using her
expertise to help guide the implementation of our growth strategy."

 

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014. The person who arranged the release of this
information is Dr Suzanne Dilly, Chief Executive Officer of the Company.

 

 

*** ENDS ***

 

For more information, please contact:

 

 ValiRx plc                                          Tel: +44 (0) 2476 796496

                                                     www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                               Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 Dr Adam Hargreaves, Shareholder Representative      Adam.Hargreaves@pathcelerate.com (mailto:Adam.Hargreaves@pathcelerate.com)

 V Formation (Public Relations)                      +44 (0) 115 787 0206

                                                     www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                                 lucy@vformation.biz

                                                     sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)    Tel: +44 (0) 20 7213 0880

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Cenkos Securities plc (Joint Broker)                Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (Joint Broker)              Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

 

About ValiRx

 

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

 

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

 

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

 

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

 

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

 

For further information, visit: www.valirx.com

 

Appendix

The following information is disclosed in respect of Ms Stella Panu (age 49)
pursuant to Schedule 2(g) of the AIM Rules for Companies. All information is
as at the date of this announcement.

 

 Current Directorships / Partnerships:  Past Directorships / Partnerships (within the last five years):

 Assecurare Limited                     Briard Holdings Limited
 EZINVST4U Ltd*                         Campsie Capital Limited
 Maven Capital (Telfer House) LLP       Dalglen (No.1148) Limited
 Metropol Communications Limited        Elite Business Development Limited
 Movere Limited*                        Fairmont Holdings Limited
 SPSAV Trading Limited*                 GeninCode plc
 Vianet Group PLC                       Legal Reports and Services Limited
                                        Litcomp Limited
                                        Manor Retailing Limited
                                        Maven Capital Partners UK LLP
                                        Maven GMLF CI LLP
                                        Perfect Consulting Limited
                                        Sopco Management Ltd
                                        The GP Service (UK) Ltd
                                        Torridon Capital Limited
 * dormant companies

 

 

In conjunction with her role at Maven, Stella is or has been a director of
several cash shells. Before 2016, venture capital trusts ("VCT"), of which
Maven manages numerous, were permitted to invest in cash shells whereby
respective investments were considered to be qualifying investments for the
purposes of VCT.  These cash shells were required to make an acquisition of a
trading business within 2 years.  If such an investment was not completed
within the 2-year time frame then the cash shell was required to return
cash/investment to respective shareholders and the entity placed into a
voluntary liquidation.  Such companies, which Stella was a director at such
time or in the 12 months following such event, are as follows:

 

 Assecurare Limited
 Briard Holdings Limited
 Dunning Capital Limited
 Manor Retailing Limited
 Metropol Communications Limited

 

 

Stella was previously a director of Dalglen (No. 1148) Limited.  This company
was one of Maven's VCT investments.  The trading assets were sold to an
acquiror in an asset sale and purchase transaction.  Following the sale of
the assets, the company was placed into voluntary liquidation and was
dissolved on 7 June 2019.  There were no outstanding amounts owed to
creditors.

Stella was previously director of Space Student Living Limited, a company in
which Maven was invested. The Company was placed into liquidation on 12
December 2012 and subsequently dissolved on 9 December 2016.  There were no
amounts outstanding to creditors.

Stella was previously a director of Wey Bridging Ltd from 25 January 2010 to
26 November 2010.  The company was placed into liquidation via a creditor's
voluntary liquidation on 2 November 2011. There were no amounts outstanding to
creditors.

Stella was previously appointed a director of Centurion Underwriting Agency
Limited, a subsidiary of Torridon Capital Limited, on 9 February 2010. On 21
December 2010 the company was placed into liquidation and subsequently
dissolved on 5 April 2011. There were no amounts outstanding to creditors.

Additionally, Stella was a director of the following companies that were
dissolved via voluntary wind-up at the time of or in the 12 months following
her directorship:

 Campsie Capital Limited
 Cox Associates Limited
 Elite Litigation Funding Limited
 Perfect Consulting Limited
 Sopco Management Limited
 SPSAV investment Limited
 SPSAV Management Company Limited

 

Ms Stella Panu does not own any ordinary shares or options over ordinary
shares in the Company.

There is no further information which is required to be disclosed under
Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of Ms
Stella Panu.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAMMBATMTJBBJT